Department of Pharmaceutical Medicines and Regulatory Science, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, Republic of Korea.
Department of Pharmacy, Inha University Hospital, Incheon, Republic of Korea.
PLoS One. 2019 May 16;14(5):e0216805. doi: 10.1371/journal.pone.0216805. eCollection 2019.
The medication regimen complexity index (MRCI), originally developed in English, is a reliable and valid tool to assess the complexity of pharmacotherapy. This study aimed to validate the Korean version of MRCI (MRCI-K). A cross-cultural methodological study comprising 335 discharged patients of a tertiary hospital in Korea was conducted. The translation process included translation into Korean by two clinical pharmacists, back translation by two native speakers, and a pretest of the tool, culminating in the Korean version of MRCI-K. Reliability analysis was assessed using inter-rater and test-retest reliability with 25 randomly selected patients. Convergent and discriminant validity analyses were conducted by correlating MRCI scores with medication number, age, sex, adverse drug reaction (ADR) reports, and length of stay. The criterion validity was confirmed through evaluation by a nine-member expert panel that subjectively ranked these regimens. The reliability analysis demonstrated excellent internal consistency (Cronbach's α = 0.977), and the intraclass correlation coefficient exceeded 0.90 for all cases. The correlation coefficient for the number of medications was 0.955 (P < 0.001). Weak significant correlations were observed with age and length of stay. The MRCI-K group with ADR reports scored higher (mean, 31.8) than the group without ADR reports (mean, 27.3). The expert panel's ranking had a stronger correlation with the MRCI ranking than the medication number ranking. MRCI-K has similar reliability and validity as MRCI and is useful for analyzing therapeutic regimens with potential applications in both practice and research in Korea.
药物治疗方案复杂指数(MRCI)最初是用英文开发的,是一种可靠有效的评估药物治疗复杂性的工具。本研究旨在验证韩国版 MRCI(MRCI-K)。这是一项跨文化的方法学研究,包括韩国一家三级医院的 335 名出院患者。翻译过程包括由两名临床药剂师进行韩文翻译、两名以英语为母语的人进行回译以及对工具进行预测试,最终形成了韩文版的 MRCI-K。采用 25 名随机选择的患者评估了评分者间信度和重测信度。通过与药物数量、年龄、性别、药物不良反应(ADR)报告和住院时间相关联,进行了 MRCI 评分的相关性和区分效度分析。通过由 9 名专家组成的小组对这些方案进行主观评分来确认标准效度。可靠性分析显示,内部一致性极好(Cronbach's α = 0.977),所有情况下的组内相关系数均超过 0.90。与药物数量的相关系数为 0.955(P < 0.001)。与年龄和住院时间也存在弱显著相关性。有 ADR 报告的 MRCI-K 组评分较高(均值为 31.8),而无 ADR 报告的组评分较低(均值为 27.3)。专家小组的评分与 MRCI 评分的相关性强于与药物数量评分的相关性。MRCI-K 具有与 MRCI 相似的可靠性和有效性,可用于分析治疗方案,在韩国的实践和研究中具有潜在应用价值。